News | Cath Lab | February 27, 2019

DABRA Excimer Laser System Demonstrates Success in Treating PAD

Study achieved a statistically significant difference in pre- and post-percent stenosis and ankle-brachial index values

DABRA Excimer Laser System Demonstrates Success in Treating PAD

February 27, 2019 — Ra Medical Systems Inc. announced a 98 percent success rate in the results from a 52-patient study using the company’s DABRA System for the treatment of above- and below-the-knee peripheral artery disease (PAD). The data was presented by Ashok Kondur, M.D., FACC, FSCAI at the 2019 Leipzig Interventional Course (LINC) in Leipzig, Germany.

The study results were overwhelmingly positive, according to the company, given the inclusion of a challenging sample of patients, all Rutherford class 4 to 6 with a high presence of calcium (80 percent of lesions had moderate to severe calcification) and 93 percent median lesion stenosis. A statistically significant difference was demonstrated in pre- and post-diameter stenosis (p<0.001), and lesion success, defined as <30 percent post diameter stenosis, was 98 percent. Furthermore, the results demonstrated statistically significant improvements in limb hemodynamic measures.

“The results of this study are extremely promising and demonstrate the positive clinical outcomes we have seen with DABRA,” said Kondur, chair, Division of Cardiology, Garden City Hospital/MSU and associate program director, Interventional Cardiology Fellowship Program, DMC Harper University Hospital, Wayne State University.

The purpose of the study was to evaluate the use of DABRA (Destruction of Arteriosclerotic Blockages by laser Radiation Ablation) in patients with above-the-knee and below-the-knee disease in a cohort of 52 patients and 111 collective lesions. Patients were treated solely with DABRA plus percutaneous coronary angioplasty (PTA), with no adjunctive stenting. Intravascular ultrasound and/or angiography was used pre- and post-treatment.

“We have seen significant changes in pre- and post-ABIs [ankle-brachial indices] and a very low complication rate with no distinct clinically or angiographically observed distal embolization,” said study lead investigator Elias Kassab, M.D., FACC, FSCAI, FACP, FASA, RPVI, FAHA, FSVM, president and CEO of Michigan Outpatient Vascular Institute and assistant professor of medicine, Wayne State University.

DABRA is a safe, versatile and simple catheter and laser system for the treatment of mixed morphology vascular blockages above- and below-the-knee. Its photochemical plaque ablating mechanism of action reduces all plaque types (calcium, thrombus and atheroma) into their fundamental chemistry with reduced mechanical, thermal and barometric trauma and minimized downstream debris.

The positive results presented at LIN 2019 are reaffirmed by Athar Ansari, M.D., DTM&H, MRCP, FACC, in his case report, Treatment of a Long, Heavily Calcified left SFA Lesion with Single-Vessel Runoff Via an Ipsilateral Antegrade Approach, published in the January issue of Endovascular Today. In the article, Ansari highlights the product’s fast and easy use with no distal embolization in yet another challenging case.

For more information: www.ramed.com


Related Content

News | Cath Lab

May 1, 2025 – Analyses from the (Ergonomics in the Cardiac Catheterization Laboratory (ERGO-CATH) study show the ...

Home May 01, 2025
Home
News | Cath Lab

March 17, 2025 — GE HealthCare recently launched the AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab. The AltiX AI ...

Home March 17, 2025
Home
News | Cath Lab

December 20, 2023 — Jason R. McCarthy, Ph.D., associate professor of biomedical research and translational medicine and ...

Home December 20, 2023
Home
News | Cath Lab

October 26, 2023 — Royal Philips, a global leader in health technology, announced the latest results demonstrating the ...

Home October 26, 2023
Home
News | Cath Lab

October 25, 2023 — Shockwave Medical, Inc., a pioneer in the development and commercialization of transformational ...

Home October 25, 2023
Home
News | Cath Lab

October 20, 2023 — Over the coming days, Philips will be presenting its latest solutions in cardiology and new late ...

Home October 20, 2023
Home
News | Cath Lab

October 16, 2023 — GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest ...

Home October 16, 2023
Home
News | Cath Lab

October 16, 2023 — Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, announced the first U.S ...

Home October 16, 2023
Home
News | Cath Lab

September 13, 2023 — A diagnostic test, first offered in the United States at University Hospitals (UH) Harrington Heart ...

Home September 13, 2023
Home
News | Cath Lab

August 2, 2023 — Teleflex Incorporated, a leading global provider of medical technologies, announced the U.S Food and ...

Home August 02, 2023
Home
Subscribe Now